Novel Inhibitors of Influenza Virus Fusion: Structure-Activity Relationship and Interaction with the Viral Hemagglutinin

ABSTRACT A new class of N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide inhibitors of influenza virus hemagglutinin (HA)-mediated membrane fusion that has a narrow and defined structure-activity relationship was identified. In Madin-Darby canine kidney (MDCK) cells infected with different strains of human influenza virus A/H3N2, the lead compound, 4c, displayed a 50% effective concentration of 3 to 23 μM and an antiviral selectivity index of 10. No activity was observed for A/H1N1, A/H5N1, A/H7N2, and B viruses. The activity of 4c was reduced considerably when added 30 min or later postinfection, indicating that 4c inhibits an early step in virus replication. 4c and its congeners inhibited influenza A/H3N2 virus-induced erythrocyte hemolysis at low pH. 4c-resistant virus mutants, selected in MDCK cells, contained either a single D112N change in the HA2 subunit of the viral HA or a combination of three substitutions, i.e., R220S (in HA1) and E57K (in HA2) and an A-T substitution at position 43 or 96 of HA2. The mutants showed efficiency for receptor binding and replication similar to that of wild-type virus yet displayed an increased pH of erythrocyte hemolysis. In polykaryon assays with cells expressing single-mutant HA proteins, the E57K, A96T, and D112N mutations resulted in 4c resistance, and the HA proteins containing R220S, A96T, and D112N mutations displayed an increased fusion pH. Molecular modeling identified a binding cavity for 4c involving arginine-54 and glutamic acid-57 in the HA2 subunit. Our studies with the new fusion inhibitor 4c confirm the importance of this HA region in the development of influenza virus fusion inhibitors.

[1]  R. Webster,et al.  The pH of Activation of the Hemagglutinin Protein Regulates H5N1 Influenza Virus Pathogenicity and Transmissibility in Ducks , 2009, Journal of Virology.

[2]  J. Jekő,,et al.  Anti-influenza virus activity and structure–activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains , 2009, Antiviral Research.

[3]  R. Webster,et al.  Amino Acid Residues in the Fusion Peptide Pocket Regulate the pH of Activation of the H5N1 Influenza Virus Hemagglutinin Protein , 2009, Journal of Virology.

[4]  R. Russell,et al.  Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. , 2009, Antiviral research.

[5]  David J Stevens,et al.  Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion , 2008, Proceedings of the National Academy of Sciences.

[6]  S. Brody,et al.  Experimental Evolution of Human Influenza Virus H3 Hemagglutinin in the Mouse Lung Identifies Adaptive Regions in HA1 and HA2 , 2008, Journal of Virology.

[7]  E. van der Vries,et al.  Fatal oseltamivir-resistant influenza virus infection. , 2008, The New England journal of medicine.

[8]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  A. Moscona,et al.  Medical management of influenza infection. , 2008, Annual review of medicine.

[10]  A. Lai,et al.  Locking the Kink in the Influenza Hemagglutinin Fusion Domain Structure* , 2007, Journal of Biological Chemistry.

[11]  M. Akkurt,et al.  2-Hydr­oxy-N-(3-oxo-1-thia-4-aza­spiro­[4.5]dec-4-yl)-2,2-diphenyl­acetamide , 2007 .

[12]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[13]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.

[14]  R. Webster,et al.  The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04 , 2006, The Journal of experimental medicine.

[15]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[16]  R. Webster,et al.  Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. , 2005, Virology.

[17]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[18]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[19]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[20]  J. Skehel,et al.  H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. , 2004, Virology.

[21]  N. Cesur,et al.  Synthesis of some new 6-methylimidazo[2,1-b]thiazole-5-carbohydrazide derivatives and their antimicrobial activities. , 2004, Arzneimittel-Forschung.

[22]  G. Ötük,et al.  Synthesis of Some New 6-Methylimid azo [2,1-b] thiazole-5-carbohydrazide Derivatives and their Antimicrobial Activities , 2004, Arzneimittelforschung.

[23]  C. Cepko,et al.  Electroporation and RNA interference in the rodent retina in vivo and in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Klenk,et al.  Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors , 2003, Journal of Virology.

[25]  D. Steinhauer,et al.  Mechanisms of cell entry by influenza virus , 2001, Expert Reviews in Molecular Medicine.

[26]  G. Whittaker,et al.  Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor. , 2000, The Journal of general virology.

[27]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Meanwell,et al.  pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion , 1999, Journal of Virology.

[29]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[30]  I D Kuntz,et al.  Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity , 1997, Journal of virology.

[31]  N. Meanwell,et al.  Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus , 1997, Journal of virology.

[32]  M. Krystal,et al.  Characterization of a hemagglutinin-specific inhibitor of influenza A virus. , 1996, Virology.

[33]  J. Skehel,et al.  Studies using double mutants of the conformational transitions in influenza hemagglutinin required for its membrane fusion activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[35]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[36]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[37]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[38]  I D Kuntz,et al.  Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. , 1993, Biochemistry.

[39]  J. Skehel,et al.  Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[41]  J. Skehel,et al.  The receptor‐binding and membrane‐fusion properties of influenza virus variants selected using anti‐haemagglutinin monoclonal antibodies. , 1987, The EMBO journal.

[42]  D. Wiley,et al.  Fusion mutants of the influenza virus hemagglutinin glycoprotein , 1985, Cell.

[43]  I. Wilson,et al.  Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[45]  F M Richards,et al.  Areas, volumes, packing and protein structure. , 1977, Annual review of biophysics and bioengineering.

[46]  N. Khardori,et al.  Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009 , 2009 .

[47]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[48]  J. J. Skehel,et al.  Influenza haemagglutinin. , 2002, Vaccine.

[49]  R. Nilakantan,et al.  Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. , 1999, Journal of virology.

[50]  T. Fujiwara,et al.  Identification of a novel HA conformational change inhibitor of human influenza virus , 1999, Archives of Virology.